Skip to main content

Table 1 Hepatic and renal function in wild-type (WT) mice and vehicle-treated, sodium vanadate (SV)-treated, L-ascorbic acid (L-AA)-treated, and L-AA+SV-treated spinal muscular atrophy (SMA) mice

From: Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy

Groups GOT (U/I) GPT (U/I) BUN (mg/dl) CRE (mg/dl)
Reference range 54 to 298 17 to 77 8 to 33 0.2 to 0.9
Postnatal day 30     
WT 55.67 ± 10.20 35.67 ± 6.67 19.82 ± 0.56 < 0.20
SMA (vehicle) 93.69 ± 20.28 30.16 ± 2.64 22.22 ± 0.77 0.23 ± 0.02
SMA (L-AA) 129.62 ± 33.65 31.15 ± 2.14 23.98 ± 0.91 0.26 ± 0.02
SMA (L-AA+SV) 119.87 ± 28.25 31.27 ± 2.99 22.80 ± 1.01 0.21 ± 0.03
Postnatal day 90     
WT 125.40 ± 30.09 57.60 ± 7.63 24.38 ± 2.65 < 0.20
SMA (vehicle) 107.05 ± 18.45 42.20 ± 4.19 22.27 ± 0.90 < 0.20
SMA (L-AA) 169.54 ± 19.09 37.69 ± 2.96 24.32 ± 0.65 < 0.20
SMA (L-AA+SV) 143.50 ± 20.66 39.62 ± 3.85 25.17 ± 1.30 < 0.20
  1. Results were determined in at least five mice in each group, and the mean ± SEM was calculated. BUN = blood urea nitrogen; CRE = creatinine; GOT = glutamate oxaloacetate transaminase; GPT = glutamate pyruvate transaminase.